Potential roles of oxidative distress on neurodegeneration in Parkinson's disease with neuropsychiatric symptoms

Background Neuropsychiatric symptoms (NPSs) belong to a category of non-motor symptoms of Parkinson's disease (PD), which seriously compromise the quality of life and prognosis of PD. This study focused on the correlations between NPSs, free radicals, neuroinflammatory factors, and neuropathological proteins in cerebrospinal fluid (CSF) in patients with PD, aiming to provide insights into the potential mechanisms and therapeutic target for PD with NPSs (PD-NPSs). Methods In total, 129 patients with PD were enrolled and assessed by the Neuropsychiatric Symptoms Inventory (NPI); they were divided into the PD-NPSs group (75 patients) and PD with no NPSs (PD-nNPSs) group (54 patients). The levels of hydrogen peroxide (H2O2) and nitric oxide (NO), and hydroxyl radical (·OH), anti-oxidative enzyme, neuroinflammatory factors, and neuropathological proteins in CSF from patients with PD were measured. The levels of the above variables were compared between PD-NPSs and PD-nNPSs groups, and correlation analyses among the above variables were conducted. Results (1) The levels of H2O2 and NO in CSF from the PD-NPSs group were significantly elevated compared with the PD-nNPSs group (p = 0.001), and NPI score positively correlated with the levels of H2O2 and NO (r = 0.283, P = 0.001; r = 0.231, P = 0.008). Reversely, total superoxide dismutase (tSOD) activity in CSF from the PD-NPSs group was significantly reduced compared with the PD-nNPSs group (p = 0.011), and negatively correlated with NPI score (r = −0.185, p = 0.036). (2) The tumor necrosis factor (TNF)-α level in CSF from the PD-NPSs group was significantly decreased compared with the PD-nNPSs group (p = 0.002) and negatively correlated with NPI score (r = −0.211, p = 0.016). (3) The total tau (T-tau) level in CSF from the PD-NPSs group was significantly higher than in the PD-nNPSs group (p = 0.014) and positively correlated with the NPI score (r = 0.167, p = 0.060). (4) The levels of H2O2 and NO positively correlated with the T-tau level in CSF from the PD-NPSs group (r = 0.183, p = 0.039; r = 0.251, P = 0.004), and the levels of TNF-α and T-tau showed a negative correlation (r = −0.163, p = 0.067). Conclusion Oxidative distress characterized by the elevations of H2O2 and NO levels may closely correlate with the neurodegeneration in brain regions related to PD-NPSs. Thus, therapeutic antioxidants may become an important target for PD-NPSs therapy.

[1]  L. Zuo,et al.  Clinical Characteristics, Iron Metabolism and Neuroinflammation: New Insight into Excessive Daytime Sleepiness in Parkinson’s Disease , 2021, Neuropsychiatric disease and treatment.

[2]  T. Révész,et al.  Neuropathological and Biomarker Findings in Parkinson’s Disease and Alzheimer’s Disease: From Protein Aggregates to Synaptic Dysfunction , 2020, Journal of Parkinson's disease.

[3]  G. Grant,et al.  Investigating the Convergent Mechanisms between Major Depressive Disorder and Parkinson’s Disease , 2020, Complex Psychiatry.

[4]  Xiao-Min Wang,et al.  Parkinson’s Disease With Depression: The Correlations Between Neuroinflammatory Factors and Neurotransmitters in Cerebrospinal Fluid , 2020, Frontiers in Aging Neuroscience.

[5]  A. Cuadrado,et al.  Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications , 2020, Cells.

[6]  Qianjun He,et al.  Nitric oxide detection methods in vitro and in vivo , 2019, Medical gas research.

[7]  D. D. Di Monte,et al.  Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular α-synuclein transfer. , 2019, The Journal of clinical investigation.

[8]  A. Schrag,et al.  Neuropsychiatric aspects of Parkinson’s disease , 2019, Journal of Neural Transmission.

[9]  L. Zuo,et al.  Tremor-Dominant in Parkinson Disease: The Relevance to Iron Metabolism and Inflammation , 2019, Front. Neurosci..

[10]  Laura Avanzino,et al.  Relationships between gait and emotion in Parkinson's disease: A narrative review. , 2018, Gait & posture.

[11]  K. Hassanzadeh,et al.  Oxidative stress and neuroinflammation in the story of Parkinson’s disease: Could targeting these pathways write a good ending? , 2018, Journal of cellular physiology.

[12]  D. Ffytche,et al.  Assessment and Management of Neuropsychiatric Symptoms in Parkinson’s Disease , 2018, CNS Drugs.

[13]  K. Hassanzadeh,et al.  Thymoquinone exerts neuroprotective effect in animal model of Parkinson's disease. , 2017, Toxicology letters.

[14]  V. Lee,et al.  Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production , 2017, Cellular and Molecular Life Sciences.

[15]  J. Schott,et al.  Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study , 2017, The Lancet Neurology.

[16]  Manoj Kumar,et al.  INGE GRUNDKE-IQBAL AWARD FOR ALZHEIMER’S RESEARCH: NEUROTOXIC REACTIVE ASTROCYTES ARE INDUCED BY ACTIVATED MICROGLIA , 2019, Alzheimer's & Dementia.

[17]  M. Kuijf,et al.  Prevalence of anxiety in Parkinson's disease: A systematic review and meta‐analysis , 2016, Movement disorders : official journal of the Movement Disorder Society.

[18]  P. Krack,et al.  Emotional manifestations of PD: Neurobiological basis , 2016, Movement disorders : official journal of the Movement Disorder Society.

[19]  Xiaomin Wang,et al.  Excessive Iron and α-Synuclein Oligomer in Brain are Relevant to Pure Apathy in Parkinson Disease , 2016, Journal of geriatric psychiatry and neurology.

[20]  Fang Wang,et al.  Parkinson's Disease with Fatigue: Clinical Characteristics and Potential Mechanisms Relevant to α-Synuclein Oligomer , 2016, Journal of clinical neurology.

[21]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[22]  N. Kandiah,et al.  Influence of depression in mild Parkinson's disease on longitudinal motor and cognitive function. , 2015, Parkinsonism & related disorders.

[23]  Fang Wang,et al.  Parkinson disease with REM sleep behavior disorder , 2015, Neurology.

[24]  H. Berendse,et al.  Depressive symptoms in Parkinson's disease are related to decreased hippocampus and amygdala volume , 2015, Movement disorders : official journal of the Movement Disorder Society.

[25]  L. Defebvre,et al.  Apathy in untreated early‐stage Parkinson disease: Relationship with other non‐motor symptoms , 2014, Movement disorders : official journal of the Movement Disorder Society.

[26]  H. Shill,et al.  Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. , 2014, Parkinsonism & related disorders.

[27]  M. Hornberger,et al.  Neuropsychiatric symptoms in Parkinson's disease: fronto-striatal atrophy contributions. , 2014, Parkinsonism & related disorders.

[28]  B. Kalyanaraman,et al.  Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. , 2014, Biochimica et biophysica acta.

[29]  L. Defebvre,et al.  Apathy in Parkinson's disease is associated with nucleus accumbens atrophy: A magnetic resonance imaging shape analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.

[30]  F. Wang,et al.  Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study , 2014, BMC Neurology.

[31]  N. Chandel,et al.  ROS Function in Redox Signaling and Oxidative Stress , 2014, Current Biology.

[32]  Stephanie D. Wilson,et al.  A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. , 2014, JAMA neurology.

[33]  Lei Liu,et al.  Oxidative stress induces gastric submucosal arteriolar dysfunction in the elderly. , 2013, World journal of gastroenterology.

[34]  Xiao-Min Wang,et al.  Sleep Disorders in Parkinson’s Disease: Clinical Features, Iron Metabolism and Related Mechanism , 2013, PloS one.

[35]  S. Gentleman,et al.  Disturbed sleep in Parkinson's disease: anatomical and pathological correlates , 2013, Neuropathology and applied neurobiology.

[36]  Sara Hall,et al.  Cerebrospinal fluid inflammatory markers in Parkinson’s disease – Associations with depression, fatigue, and cognitive impairment , 2013, Brain, Behavior, and Immunity.

[37]  R. de la Fuente-Fernández Imaging of Dopamine in PD and Implications for Motor and Neuropsychiatric Manifestations of PD , 2013, Front. Neurol..

[38]  D. Surmeier,et al.  Calcium Entry and α-Synuclein Inclusions Elevate Dendritic Mitochondrial Oxidant Stress in Dopaminergic Neurons , 2013, The Journal of Neuroscience.

[39]  R. Camicioli,et al.  Intact limbic-prefrontal connections and reduced amygdala volumes in Parkinson's disease with mild depressive symptoms. , 2012, Parkinsonism & related disorders.

[40]  M. Martínez-Banaclocha N-acetyl-cysteine in the treatment of Parkinson's disease. What are we waiting for? , 2012, Medical hypotheses.

[41]  Kathleen R. Bogart Is apathy a valid and meaningful symptom or syndrome in Parkinson's disease? A critical review. , 2011, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[42]  Yi Zhu,et al.  Leonurine Protects Middle Cerebral Artery Occluded Rats Through Antioxidant Effect and Regulation of Mitochondrial Function , 2010, Stroke.

[43]  Wim E J Weber,et al.  Neuroanatomical correlates of apathy in Parkinson's disease: A magnetic resonance imaging study using voxel‐based morphometry , 2010, Movement disorders : official journal of the Movement Disorder Society.

[44]  M Filippi,et al.  Regional patterns of brain tissue loss associated with depression in Parkinson disease , 2010, Neurology.

[45]  L. Tremblay,et al.  Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. , 2010, Brain : a journal of neurology.

[46]  Guido Alves,et al.  Epidemiology of psychosis in Parkinson's disease , 2010, Journal of the Neurological Sciences.

[47]  João Ricardo Sato,et al.  Depression in Parkinson's disease: Convergence from voxel-based morphometry and functional magnetic resonance imaging in the limbic thalamus , 2009, NeuroImage.

[48]  C. Ríos,et al.  Free Copper, Ferroxidase and SOD1 Activities, Lipid Peroxidation and NOx Content in the CSF. A Different Marker Profile in Four Neurodegenerative Diseases , 2008, Neurochemical Research.

[49]  Z. Illés,et al.  Morphometric changes of gray matter in Parkinson's disease with depression: A voxel‐based morphometry study , 2008, Movement disorders : official journal of the Movement Disorder Society.

[50]  M. Barrachina,et al.  Abnormal levels of prohibitin and ATP synthase in the substantia nigra and frontal cortex in Parkinson's disease , 2007, Neuroscience Letters.

[51]  J. Snaedal,et al.  Ceruloplasmin and superoxide dismutase (SOD1) in Parkinson's disease: A follow-up study , 2006, Journal of the Neurological Sciences.

[52]  C. Marsden,et al.  A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.

[53]  R. Marttila,et al.  Oxygen toxicity protecting enzymes in Parkinson's disease Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus , 1988, Journal of the Neurological Sciences.

[54]  R. Hider,et al.  Colorimetric detection of the hydroxyl radical: comparison of the hydroxyl-radical-generating ability of various iron complexes. , 1988, Analytical biochemistry.

[55]  D. Aarsland,et al.  Neuropsychiatric Symptoms in Parkinson's Disease. , 2015, Journal of Parkinson's disease.